42-1611495 · Portsmouth, VA
To develop and test vaccines for the prevention and treatment of cancer in murine cancer models
Total revenue
$3.1M
FY2023
Total expenses
$27.7K
FY2023
Net assets
$3.5M
FY2023
Operating margin
99.1%
NPLens analysis
FY17–FY2023 · from annual filings
Financial health
A+
Derived analysis — not an official IRS designation.
Computed from FY2023 · derived analysis
FY2023 · program vs. administration vs. fundraising (Form 990, Part IX)
FY2023 · where revenue comes from (as reported)
Highest-paid officers, directors & key employees · FY2023.
Ruby Kochhar MD
President
$0
Jay Umbreit MD PhD
Board Member
$0
Mark Wilkowski MD
Board Member
$0
Each figure on this page traces to one of these source returns.
Health scores, efficiency ratios, peer percentiles, and outlier flags are derived analysis by NPLens — not official IRS designations. Figures are as reported on the organization's Form 990 filings. How these are computed →